- Discovery of a Potent and Orally Bioavailable Melatonin Receptor Agonist
-
To develop potent and orally bioavailable melatonin receptor (MT1 and MT2) agonists, a novel series of 5-6-5 tricyclic derivatives was designed, synthesized, and evaluated. The synthesized indeno[5,4-d][1,3]oxazole, cyclopenta[c]pyrazolo[1,5-a]pyridine, i
- Hoashi, Yasutaka,Takai, Takafumi,Kosugi, Yohei,Nakashima, Masato,Nakayama, Masaharu,Hirai, Keisuke,Uchikawa, Osamu,Koike, Tatsuki
-
p. 3059 - 3074
(2021/04/06)
-
- DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS
-
Compounds of formula I: I are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.
- -
-
Paragraph 0282
(2018/03/28)
-
- TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF
-
The present invention provides a compound represented by the formula wherein R1 is a hydrocarbon group optionally having substituent(s), amino optionally having substituent(s), hydroxy optionally having a substituent or a heterocyclic group opt
- -
-
Page/Page column 54-55
(2009/09/26)
-
